文献速递淋巴瘤

老年套细胞淋巴瘤长期随访:欧洲MCL老年试验更新

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
PubMed 文献 · J Clin Oncol · 2019-12-05

该更新报告了随机III期欧洲MCL老年试验的长期随访结果,中位随访7.6年。R-CHOP应答者接受利妥昔单抗维持较干扰素α显著延长无进展生存期和总生存期。

要点

  • R-CHOP诱导后利妥昔单抗维持至进展在老年MCL中长期有效且安全。
  • R-FC诱导后利妥昔单抗维持与5年累积缓解期死亡发生率22%相关。
  • R-CHOP后利妥昔单抗维持超过2年仍有效且安全。

核心结论

  • R-CHOP后利妥昔单抗维持至进展在老年MCL患者中的优异结果在成熟随访中持续存在。

研究设计与样本

  • 316例应答者进行第二次随机(利妥昔单抗 vs 干扰素α维持,直至进展)。

主要发现

  • R-CHOP治疗患者中,58%和32%在维持开始后2年和5年仍在接受利妥昔单抗维持。
  • R-FC后利妥昔单抗维持与意外高的5年累积缓解期死亡发生率22%相关。
  • R-CHOP后利妥昔单抗维持的3-4级白细胞减少或感染<5%;R-FC后利妥昔单抗维持的3-4级白细胞减少高达40%,感染高达15%。

临床怎么用

  • 老年MCL患者可考虑R-CHOP诱导后利妥昔单抗维持至进展。
  • R-FC后利妥昔单抗维持需警惕缓解期死亡风险及血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance. PATIENTS AND METHODS: Five hundred sixty patients with newly diagnosed MCL underwent a first random assignment between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, fludarabine, and cyclophosphamide (R-FC) induction, followed by a second random assignment in 316 responders between rituximab and interferon alfa maintenance, to be continued until progression. We compared progression-free survival from the second randomization and overall survival (OS) from the first or second randomizations. RESULTS: After a median follow-up time of 7.6 years, the previously described difference in OS between the induction arms persisted (median, 6.4 years after R-CHOP [n = 280] v 3.9 years after R-FC [n = 280]; P = .0054). Patients responding to R-CHOP had median progression-free survival and OS times of 5.4 and 9.8 years, respectively, when randomly assigned to rituximab (n = 87), compared with 1.9 years (P < .001) and 7.1 years (P = .0026), respectively, when randomly assigned to interferon alfa (n = 97). In 58% and 32% of patients treated with R-CHOP, rituximab maintenance was still ongoing 2 and 5 years from start of maintenance, respectively. After R-FC, rituximab maintenance was associated with an unexpectedly high cumulative incidence of death in remission (22% at 5 years). Toxicity of rituximab maintenance was low after R-CHOP (grade 3-4 leukopenia or infection < 5%) but more prominent in patients on rituximab maintenance after R-FC, in whom grade 3-4 leukopenia (up to 40%) and infections were frequent (up to 15%). CONCLUSION: The excellent results of R-CHOP followed by rituximab maintenance until progression for older patients with MCL persisted in a mature follow-up. Prolongation of rituximab maintenance beyond 2 years is effective and safe.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2019. PMID: 31804876. doi:10.1200/JCO.19.01294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。